Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
05 nov. 2020 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in...
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
16 oct. 2020 07h30 HE
|
Novartis International AG
If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9...
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial
01 oct. 2020 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
High accuracy in predicting advanced NASH fibrosis (F2-F3) in Phase 3 MAESTRO-NASH study using clinical characteristics and simple, readily available non-invasive imaging and biomarkersData from...
Study: Reducing Lead Exposure Has Massive Benefit for Adult Population
23 sept. 2020 10h11 HE
|
Abt Associates
Rockville, Md., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Rockville, Md. – An Abt Associates-led study finds that reduction in lead exposure over the past 15 years has decreased the number of...
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
03 sept. 2020 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
--Completion of enrollment in MAESTRO-NAFLD-1 will enable reporting of topline 52-week data by the end of next year as planned.--Madrigal intends to present selected data from ongoing open label arm...
$1.3 Billion AI in Diagnostics Industry Assessment 2020-2026 by Diagnosis Type, Component and Region
26 août 2020 08h21 HE
|
Research and Markets
Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Artificial Intelligence in Diagnostics Market By Diagnosis Type (Radiology, Oncology, Neurology, Cardiology, Chest & Lungs, Pathology and...
Highlights: 2020 Cardiometabolic Health Congress West Live Online
21 août 2020 11h00 HE
|
Cardiometabolic Health Congress
Boca Raton, Aug. 21, 2020 (GLOBE NEWSWIRE) -- The 4th Annual CMHC West: Complexities in Cardiometabolic Care was held live online on Aug 7-9, 2020, and was chaired by top experts: Christie M....
A startup that monitors heart health with a toilet seat joins Innovators’ Network
28 juil. 2020 06h00 HE
|
Heart Health Intelligence
ROCHESTER, N.Y., July 28, 2020 (GLOBE NEWSWIRE) -- Heart Health Intelligence (HHI) has joined the American Heart Association’s Center for Health Technology & Innovation’s (the Center)...
Heart Health Intelligence Raises Funds for a Revolutionary In-Home Cardiovascular Monitoring Device
01 avr. 2020 11h00 HE
|
Heart Health Intelligence
ROCHESTER, N.Y., April 01, 2020 (GLOBE NEWSWIRE) -- Given the current COVID-19 pandemic, the ability to monitor cardiovascular health in the home has become critical to reduce the burden on...
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
28 mars 2020 11h00 HE
|
Novartis International AG
Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified...